KR20220150313A - Pick1의 지질 접합 펩티드 억제제 - Google Patents

Pick1의 지질 접합 펩티드 억제제 Download PDF

Info

Publication number
KR20220150313A
KR20220150313A KR1020227031597A KR20227031597A KR20220150313A KR 20220150313 A KR20220150313 A KR 20220150313A KR 1020227031597 A KR1020227031597 A KR 1020227031597A KR 20227031597 A KR20227031597 A KR 20227031597A KR 20220150313 A KR20220150313 A KR 20220150313A
Authority
KR
South Korea
Prior art keywords
pick1
peptide
inhibitor
npeg
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227031597A
Other languages
English (en)
Korean (ko)
Inventor
케네스 엘. 매드센
울릭 게테르
니콜라이 리스 크리스텐센
Original Assignee
유니버시티 오브 코펜하겐
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 코펜하겐 filed Critical 유니버시티 오브 코펜하겐
Publication of KR20220150313A publication Critical patent/KR20220150313A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
KR1020227031597A 2020-03-06 2021-03-05 Pick1의 지질 접합 펩티드 억제제 Pending KR20220150313A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20161493 2020-03-06
EP20161493.0 2020-03-06
PCT/EP2021/055678 WO2021176094A1 (en) 2020-03-06 2021-03-05 Lipid conjugated peptide inhibitors of pick1

Publications (1)

Publication Number Publication Date
KR20220150313A true KR20220150313A (ko) 2022-11-10

Family

ID=69780027

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227031597A Pending KR20220150313A (ko) 2020-03-06 2021-03-05 Pick1의 지질 접합 펩티드 억제제

Country Status (10)

Country Link
US (1) US20230346948A1 (cg-RX-API-DMAC7.html)
EP (1) EP4114524A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023506598A (cg-RX-API-DMAC7.html)
KR (1) KR20220150313A (cg-RX-API-DMAC7.html)
CN (1) CN115362001A (cg-RX-API-DMAC7.html)
AU (1) AU2021232645B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022017673A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168324A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022011051A (cg-RX-API-DMAC7.html)
WO (1) WO2021176094A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2111413A2 (en) * 2007-02-16 2009-10-28 Genetech, Inc. Htra1-pdz and htra3-pdz modulators
KR102046830B1 (ko) * 2011-05-13 2019-11-20 코벤하븐스 유니버시테트 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 psd-95의 고-친화성, 이량체 저해제
PL3074032T3 (pl) * 2013-12-01 2019-06-28 University Of Copenhagen Pochodne kwasów tłuszczowych dimerycznych inhibitorów psd-95
WO2020083905A1 (en) 2018-10-22 2020-04-30 University Of Copenhagen Inhibitors of pick1 and uses thereof

Also Published As

Publication number Publication date
BR112022017673A2 (pt) 2022-11-08
AU2021232645B2 (en) 2026-07-09
WO2021176094A1 (en) 2021-09-10
US20230346948A1 (en) 2023-11-02
AU2021232645A1 (en) 2022-09-15
CA3168324A1 (en) 2021-09-10
CN115362001A (zh) 2022-11-18
EP4114524A1 (en) 2023-01-11
JP2023506598A (ja) 2023-02-16
MX2022011051A (es) 2022-12-15

Similar Documents

Publication Publication Date Title
EP2714096B1 (en) Compositions and methods for transport across the blood brain barrier
WO2010043049A1 (en) Etoposide and doxorubicin conjugates for drug delivery
AU2019247467B2 (en) Compstatin analogs with increased solubility and improved pharmacokinetic properties
US12419839B2 (en) Methods and compositions for targeted delivery of protein fragments
KR20100015786A (ko) 환형의 수용체-연관된 단백질(rap) 펩티드
WO2013056096A1 (en) Polypeptide-opioid conjugates and uses thereof
TWI880227B (zh) 澱粉素類似物之液體調配物
US12590130B2 (en) Bipartite molecules and uses thereof in treating diseases associated with abnormal protein aggregates
JP2014513066A (ja) 抗新生物及び抗血管新生活性を有する環状ペプチド
JP2016516054A (ja) コレステロール流出を刺激する、減少した毒性を有するペプチド
Jolivalt et al. Therapeutic efficacy of prosaposin-derived peptide on different models of allodynia
JP2015521636A (ja) in−vivoで神経変性疾患(特にアルツハイマー病)に活性なリポソーム
US20230346948A1 (en) Lipid conjugated peptide inhibitors of PICK1
Chang et al. A newly designed molecule J2326 for Alzheimer's disease disaggregates amyloid fibrils and induces neurite outgrowth
KR20220110278A (ko) 타우병증을 치료하기 위한 펩타이드 조성물 및 방법
HU231182B1 (hu) A ß-amiloid toxicitását gátló kis peptid inhibitorok
EP3787661B1 (en) Combination of temozolomide and a par-1 conjugate for treating glioblastoma
KR102792913B1 (ko) 간/지방조직 이중 표적 복합 나노 약물 전달체
US20250367266A1 (en) Oral pharmaceutical composition for prevention or treatment of osteoporosis containing teriparatide and method for preparation thereof
KR20260044564A (ko) 포비돈-프러시안 블루 나노자임을 유효성분으로 포함하는 골관절염의 예방, 치료 또는 개선용 조성물
HK40055788A (en) Compositions and methods for transport across the blood brain barrier
WO2015105957A1 (en) Pten antagonist peptides and methods of using the same
Annunzi N-Myristoylation
WO2018129506A2 (en) Ang (1-7) derviative oligopeptides for the treatment of pain
WO2009153418A1 (fr) Peptides harp inhibant la croissance tumorale

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000